Founded in 1967 and based in Stonehouse, Gloucestershire, England, Xograph is the largest independent medical imaging equipment supplier throughout the UK and Ireland serving NHS and HSE hospitals, private hospitals, clinics and diagnostic centres. Xograph Healthcare provide innovative medical imaging technology, supported by a nationwide team of highly trained field-based engineers and clinical applications specialists.
Healthcare 21 Group Chairman Owen Curtin said: “The acquisition of Xograph Healthcare maintains our exciting period of growth and expansion, accelerating our drive to become a pan European, best in class provider of specialist sales, marketing and technical service solutions for our world leading healthcare and scientific supplier partners.”
Mr Curtin added that “Acquiring Xograph confirms our commitment to the highly innovative MedTech and Diagnostic Technical services industry. The Xograph business, combined with our existing teams, now makes the Healthcare 21 Group one the largest players in the sector across the UK and Irish healthcare market.”
The newly combined business will employ up to 500 staff in Ireland, UK, Germany and Austria and has a turnover in excess of €160m and representing more than 100 Original Equipment Manufacturers across its four European markets.
Xograph Managing Director, Paul Andrews commented “What an exciting time this is. I am so proud to be leading Xograph Healthcare, medical diagnostic imaging specialist, at this moment in the Company’s 53 year history. As the newest member of the Healthcare 21 team we can now realise new growth potential, share best practices with other HC21 business units and deliver customer service excellence with every interaction”.
This latest acquisition supports the significant expansion programme of the Healthcare 21 Group that, in less than three years, has seen the company nearly triple in size. Healthcare 21 Group is focussed on increasing its portfolio scope within its existing partners as well as continuing to look for new partners and acquisition opportunities as it targets further Irish, UK and European expansion.